CXCL9 and neoplasm: For example, whole exome and transcriptomic analysis of >1000 tumors treated with immune checkpoint inhibitors (across seven tumor types) showed that an elevated clonal tumor mutational burden, coupled with increased expression of CXCL9 (an IFN-inducible gene), is predictive of superior response [163].